CCEL
CRYO CELL INTERNATIONAL INC
NASDAQ · Healthcare · Medical - Care Facilities · US
$4.65
+5.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 31.1M | 31.6M | 32.0M | 31.3M | 30.3M |
| Cost of Revenue | 6.9M | 7.4M | 7.9M | 8.4M | 8.8M |
| Gross Profit | 24.3M | 24.2M | 24.0M | 22.9M | 21.5M |
| Operating Expenses | |||||
| R&D Expense | 303.9K | 376.3K | 1.2M | 1.2M | 384.8K |
| SG&A Expense | 18.9M | 18.2M | 18.5M | 17.1M | 15.6M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 4.9M | 751.5K | 794.3K | 16.9M | 1.6M |
| Total Operating Expenses | 24.1M | 19.3M | 20.6M | 35.2M | 17.5M |
| Cost and Expenses | 30.9M | 26.7M | 28.5M | 43.6M | 26.3M |
| Operating Income (EBIT) | 189.4K | 4.8M | 3.5M | (12.3M) | 4.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 1.8M | 2.1M | 1.9M | 1.2M | 1.5M |
| Net Interest Income | (1.8M) | (2.1M) | (1.9M) | (1.2M) | (1.5M) |
| Other Non-Op Income/Expense | (2.1M) | (7.2M) | (676.2K) | (1.1M) | (705.5K) |
| Non-Operating Income (excl Interest) | 343.0K | 5.1M | 2.5M | (176.3K) | (816.2K) |
| EBT (Pre-Tax Income) | (1.9M) | (2.3M) | 2.8M | (13.4M) | 3.3M |
| Income Tax Expense | 910.0K | 92.2K | 2.4M | (3.8M) | 547.5K |
| Bottom Line | |||||
| Net Income | (2.8M) | (2.4M) | 402.1K | (9.5M) | 2.8M |
| Earnings from Cont. Ops | (2.8M) | (2.4M) | 402.1K | (9.5M) | 2.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (2.8M) | (2.4M) | 402.1K | (9.5M) | 2.8M |
| Per Share | |||||
| Basic EPS | ($0.22) | ($0.30) | $0.05 | ($1.14) | $0.33 |
| Diluted EPS | ($0.22) | ($0.30) | $0.05 | ($1.14) | $0.33 |
| Revenue Per Share | $3.86 | $3.91 | $3.93 | $3.76 | $3.58 |
| Shares | |||||
| Basic Shares Outstanding | 8.1M | 8.1M | 8.1M | 8.3M | 8.5M |
| Diluted Shares Outstanding | 8.1M | 8.1M | 8.2M | 8.3M | 8.5M |
| Profitability Metrics | |||||
| EBITDA | 1.2M | 1.1M | 2.0M | (10.4M) | 6.7M |
| D&A | 1.3M | 1.4M | 1.0M | 1.7M | 1.8M |
| EBIT | (153.6K) | (270.9K) | 939.4K | (12.1M) | 4.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Aug 1, 2026